Stockreport

Verona Pharma PLC Reports Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]

Verona Pharma plc - American Depositary Shares  (VRNA) 
US:NASDAQ Investor Relations: nasdaq.com/symbol/vrna/real-time
PDF R&D Expenses : Decreased to $17.2 million in 2023 from $49.3 million in 2022, reflecting completion of ENHANCE program activities. SG&A Expenses : Rose to $50.4 milli [Read more]